Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia 2013 Oct;27(10):2075-7
Date
06/04/2013Pubmed ID
23728080Pubmed Central ID
PMC4053943DOI
10.1038/leu.2013.148Scopus ID
2-s2.0-84885595409 (requires institutional sign-in at Scopus site) 47 CitationsAuthor List
Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, Van Ness BAuthor
Siegfried Janz MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsAntineoplastic Agents
Boronic Acids
Bortezomib
Disease Models, Animal
Drug Resistance, Neoplasm
Flow Cytometry
Humans
Mice
Multiple Myeloma
Prognosis
Pyrazines
Receptors, CXCR4
Sarcoma, Myeloid
Survival Rate
